You just read:

CARsgen Therapeutics Receives US FDA Orphan Drug Designation For Fully Human Anti-BCMA (B Cell Maturation Antigen) Autologous Chimeric Antigen Receptor (CAR) T Cells For The Treatment Of Multiple Myeloma

News provided by

CARsgen Therapeutics Co. Ltd.

Aug 30, 2019, 22:54 ET